Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Drug Development
First-in-Class Ain’t What It Used to Be

In the pharmaceutical sector, the amount of time in which a new product has a market all to itself has diminished considerably over the past several decades. By the late 1990s, it wasn’t uncommon for a first-in-class drug (the first drug to use a particular molecular mechanism to treat a condition) to have several competitors in various stages of clinical development – even before it was approved. A few decades ago, a new drug would have a corner on the market for about eight years. Now, that figure is closer to two years.


0 comments about this story. Start the discussion »

Tagged: Business

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me